Aptose Biosciences Inc. 8-K

What Happened
Aptose Biosciences, Inc. (APTOF) filed a Form 8-K on April 30, 2026 to disclose that it issued a press release on that date. The press release is attached to the Form 8-K as Exhibit 99.1 and the filing cites Item 7.01 (Regulation FD disclosure) and Item 9.01 (exhibits). The company states, under General Instruction B.2 of Form 8-K, that the press release is furnished for purposes of Regulation FD and is not “filed” for Section 18 liability or automatically incorporated by reference into future filings.

Key Details

• Filing date: April 30, 2026; SEC accession no. 0001171843-26-002877.
• Exhibit included: Press Release dated April 30, 2026 (Exhibit 99.1).
• Disclosure type: Item 7.01 — Regulation FD disclosure (information furnished, not deemed “filed” under Section 18).
• Additional exhibit: Inline XBRL cover page embedded in the filing.

Why It Matters
This 8-K signals that Aptose made a public announcement on April 30, 2026; investors should read the attached press release (Exhibit 99.1) for any material news (e.g., clinical, partnership, financial, or corporate developments). Note the filing’s legal point: because the release is furnished under Reg FD and not “filed,” it is publicly disclosed but not subject to Section 18 liability or automatic incorporation by reference into other filings unless explicitly referenced. For the substance of the announcement, review the press release itself on EDGAR or Aptose’s investor relations page.